Paul Schneider
Director of Finance/CFO at FREELINE THERAPEUTICS HOLDINGS PLC
Profile
Paul M.
Schneider is currently the Chief Financial Officer at Freeline Therapeutics Holdings Plc.
Prior to his current position, he served as the Senior Vice President-Finance at Casebia Therapeutics LLC from 2016 to 2019.
He also held the position of Senior Vice President-Finance & Operations at Exo Therapeutics, Inc. Mr. Schneider completed his undergraduate degree at Boston College.
Paul Schneider active positions
| Companies | Position | Start |
|---|---|---|
| FREELINE THERAPEUTICS HOLDINGS PLC | Director of Finance/CFO | 2022-05-15 |
Former positions of Paul Schneider
| Companies | Position | End |
|---|---|---|
Casebia Therapeutics LLC
 Casebia Therapeutics LLC Pharmaceuticals: GenericHealth Technology Casebia Therapeutics LLC is a joint venture company that focuses on discovering, developing, and commercializing gene-editing therapeutics to treat genetic causes of bleeding disorders and autoimmune diseases. The company is based in Cambridge, MA. | Corporate Officer/Principal | 2019-08-31 |
Exo Therapeutics, Inc.
 Exo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Exo Therapeutics, Inc. engages in production of drugs. It has developed a small-molecule enzyme inhibitor discovery platform that targets distal binding pockets of enzymes (exo-sites) that are not evolutionarily conserved. The company was founded by David R. Liu and Alan Saghatelian and is headquartered in Boston, MA. | Director of Finance/CFO | - |
Training of Paul Schneider
| Boston College | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 3 |
|---|---|
Casebia Therapeutics LLC
Casebia Therapeutics LLC Pharmaceuticals: GenericHealth Technology Casebia Therapeutics LLC is a joint venture company that focuses on discovering, developing, and commercializing gene-editing therapeutics to treat genetic causes of bleeding disorders and autoimmune diseases. The company is based in Cambridge, MA. | Health Technology |
Exo Therapeutics, Inc.
Exo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Exo Therapeutics, Inc. engages in production of drugs. It has developed a small-molecule enzyme inhibitor discovery platform that targets distal binding pockets of enzymes (exo-sites) that are not evolutionarily conserved. The company was founded by David R. Liu and Alan Saghatelian and is headquartered in Boston, MA. | Health Technology |
Freeline Therapeutics Holdings Plc
 Freeline Therapeutics Holdings Plc BiotechnologyHealth Technology Freeline Therapeutics Holdings Plc engages in the business of developing and commercializing gene therapies. It also develops gene therapies for bleeding and other debilitating disorders. The company was founded by Markus Hörer and Amit Chunilal Nathwani in 2015 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Paul Schneider